# Atossa Genetics Signs National Distribution Agreement With Thermo Fisher Scientific for FullCYTE Breast Aspirator

February 9, 2015 1:00 PM EST

SEATTLE, WA--(Marketwired - Feb 9, 2015) - **Atossa Genetics Inc.** (NASDAQ: ATOS), the Breast Care Company, has signed an agreement with Thermo Fisher Scientific for distribution of Atossa's FullCYTE Breast Aspirator device in the United States through the Fisher HealthCare channel. Atossa's FullCYTE Breast Aspirator is used by physicians and nurses to collect nipple aspirate fluid from a patient's breasts for cytological analysis.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "Access to the hospital market, including breast clinics and women's health centers, is a critical part of our launch strategy for the FullCYTE Breast Aspirator in the United States. Fisher HealthCare is a recognized leader in providing medical device solutions through their world class sales and marketing team. We couldn't be more pleased to work with their organization."

**About Atossa Genetics**

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

**Forward-Looking Statements**

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.